A novel diagnostic biosensor for distinguishing immunoglobulin mutated and unmutated types of chronic lymphocytic leukemia

Ensafi, Ali A.; Amini, Maryam; Rezaei, Behzad; Talebi, Majid

doi:10.1016/j.bios.2015.09.063

Cited by 20 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It attacks the joints that connect bones. A group of researchers from the University of Wollongong, Australia, has assembled a new method for arthritic disease (Soni and Yadav, 2015;Ensafi et al, 2016;Zhang Q. et al, 2016). They introduced an antidrug that can be used through binding with Au nanoparticles, but it has some minor drawbacks.…”

Section: Therapeutic Applicationsmentioning

confidence: 99%

Recent Advances in Metal Decorated Nanomaterials and Their Various Biological Applications: A Review

et al. 2020

View full text Add to dashboard Cite

Nanoparticles (nanoparticles) have received much attention in biological application because of their unique physicochemical properties. The metal-and metal oxide-supported nanomaterials have shown significant therapeutic effect in medical science. The mechanisms related to the interaction of nanoparticles with animal and plant cells can be used to establish its significant role and to improve their activity in health and medical applications. Various attempts have been made to discuss the antibiotic resistance and antimicrobial activity of metal-supported nanoparticles. Despite all these developments, there is still a need to investigate their performance to overcome modern challenges. In this regard, the present review examines the role of various types of metal-supported nanomaterials in different areas such as antibacterial, antifungal, anticancer, and so on. Based on the significant ongoing research and applications, it is expected that metal-supported nanomaterials play an outstanding role not only in medical but also in other important areas.

show abstract

Section: Therapeutic Applicationsmentioning

confidence: 99%

Recent Advances in Metal Decorated Nanomaterials and Their Various Biological Applications: A Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…CLL is characterized by the clonal expansion and accumulation of malignant B-cells in the blood stream and homing tissues (such as bone marrow and lymphoid organs). In the CLL context, positive status of ZAP70, unmutated IgVH, as well as the presence of the chromosomal aberrations del17p and del11q —spanning TP53 and ATM locus, respectively—are considered as poor outcome predictors ( 1 – 3 ).…”

Section: Introductionmentioning

confidence: 99%

Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes

Galicia-Vázquez

Aloyz

2018

Front. Oncol.

View full text Add to dashboard Cite

Chronic Lymphocytic Leukemia (CLL) is an incurable disease, characterized by the accumulation of malignant B-lymphocytes in the blood stream (quiescent state) and homing tissues (where they can proliferate). In CLL, the targeting of B-cell receptor signaling through a Burton's tyrosine kinase inhibitor (ibrutinib) has rendered outstanding clinical results. However, complete remission is not guaranteed due to drug resistance or relapse, revealing the need for novel approaches for CLL treatment. The characterization of metabolic rewiring in proliferative cancer cells is already being applied for diagnostic and therapeutic purposes, but our knowledge of quiescent cell metabolism—relevant for CLL cells—is still fragmentary. Recently, we reported that glutamine metabolism in primary CLL cells bearing the del11q deletion is different from their del11q negative counterparts, making del11q cells especially sensitive to glutaminase and glycolysis inhibitors. In this work, we used our primary CLL lymphocyte bank and compounds interfering with central carbon metabolism to define metabolic traits associated with ibrutinib resistance. We observe a differential basal metabolite uptake linked to ibrutinib resistance, favoring glutamine uptake and catabolism. Upon ibrutinib treatment, the redox balance in ibrutinib resistant cells is shifted toward NADPH accumulation, without an increase in glutamine uptake, suggesting alternative metabolic rewiring such as the activation of fatty acid oxidation. In accordance to this idea, the curtailing of fatty acid oxidation by CPT1 inhibition (etomoxir) re-sensitized resistant cells to ibrutinib. Our results suggest that fatty acid oxidation could be explored as a target to overcome ibrutinib resistance.

show abstract

“…The biosensor can detect with a detection limit ZAP70 DNA sequence of 4.0 × 10 −15 molL −1 and a decent calibration range between 2.0 × 10 –14 and 1.0 × 10 −9 molL −1 . This biosensor is thought to be the most informative stage-independent prognostic indicator for CLL patients [ 72 ]. Another application of AuNPS was done by Mazloum-Ardakani et al to synthesize a stable composite with electrical properties, on the surface of a biosensor by synthesizing poly (catechol) with enhanced conducting properties by modification with graphene sheets and loading on AuNPS, i.e., made up of conductive polymers and nanoparticles.…”

Section: Nanotechnology Approachesmentioning

confidence: 99%

Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials

Salama,

Aborehab,

El Mahdy

et al. 2023

Eur J Med Res

View full text Add to dashboard Cite

Leukemia is a group of malignant disorders which affect the blood and blood-forming tissues in the bone marrow, lymphatic system, and spleen. Many types of leukemia exist; thus, their diagnosis and treatment are somewhat complicated. The use of conventional strategies for treatment such as chemotherapy and radiotherapy may develop many side effects and toxicity. Hence, modern research is concerned with the development of specific nano-formulations for targeted delivery of anti-leukemic drugs avoiding toxic effects on normal cells. Nanostructures can be applied not only in treatment but also in diagnosis. In this article, types of leukemia, its causes, diagnosis as well as conventional treatment of leukemia shall be reviewed. Then, the use of nanoparticles in diagnosis of leukemia and synthesis of nanocarriers for efficient delivery of anti-leukemia drugs being investigated in in vivo and clinical studies. Therefore, it may contribute to the discovery of novel and emerging nanoparticles for targeted treatment of leukemia with less side effects and toxicities.

show abstract

A novel diagnostic biosensor for distinguishing immunoglobulin mutated and unmutated types of chronic lymphocytic leukemia

Cited by 20 publications

References 36 publications

Recent Advances in Metal Decorated Nanomaterials and Their Various Biological Applications: A Review

Recent Advances in Metal Decorated Nanomaterials and Their Various Biological Applications: A Review

Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes

Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials

Contact Info

Product

Resources

About